# Camlipixant PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/camlipixant

> The next catalyst for camlipixant, sponsored by GSK plc (GSK), is its topline data readout, Mar to Jun 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | camlipixant |
| Codes | BLU-5937 |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Irritable Bowel Syndrome](https://sec-api.dev/indications/irritable-bowel-syndrome), [Refractory Chronic Cough](https://sec-api.dev/indications/refractory-chronic-cough) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Irritable Bowel Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07519395 (A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07519395

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Irritable Bowel Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07519395 (A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-09 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07519395

### Aug to Nov 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Refractory Chronic Cough.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07650084 (A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07650084

### August 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Refractory Chronic Cough.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07650084 (A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08-27 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07650084

## Same indication

- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Eluxadoline](https://sec-api.dev/pdufa/eluxadoline) (ABBV)
- [Nal er](https://sec-api.dev/pdufa/nal-er) (TRVI)

Calendar months: [March 2027](https://sec-api.dev/fda-calendar/2027-03), [August 2027](https://sec-api.dev/fda-calendar/2027-08)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/camlipixant.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Camlipixant PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/camlipixant

```bibtex
@misc{secapidev_pdufa_camlipixant_20261116,
  title        = {Camlipixant PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/camlipixant}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_camlipixant_20261116","title":"Camlipixant PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/camlipixant","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
